Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686

BACKGROUND: ACRIN 6686/RTOG 0825 was a phase III trial of conventional chemoradiation plus adjuvant temozolomide with bevacizumab or without (placebo) in newly diagnosed glioblastoma. This study investigated whether changes in contrast-enhancing and fluid attenuated inversion recovery (FLAIR)–hyperi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Boxerman, Jerrold L, Zhang, Zheng, Safriel, Yair, Rogg, Jeffrey M, Wolf, Ronald L, Mohan, Suyash, Marques, Helga, Sorensen, A Gregory, Gilbert, Mark R, Barboriak, Daniel P
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Neuroimaging
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6120359/
https://ncbi.nlm.nih.gov/pubmed/29590461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy049
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados